This study is looking for adults aged 18-65 who have both asthma and obesity. The main goal is to see if a drug called CXA-10 can help reduce inflammation in people with asthma that is made worse by obesity. Participants will receive either CXA-10 or a matching placebo (an inactive substance) for six weeks. Researchers will measure changes in your lung function, specifically how your airways react to a substance called methacholine (a test to measure airway sensitivity) and your FEV1 (a measure of how much air you can force out of your lungs in one second). The study aims to understand if CXA-10 can safely and effectively suppress the body-wide and airway inflammation linked to asthma in obese individuals. The current recruitment status is unclear.

Study design

This is a Phase 2, double-blind, placebo-controlled crossover study, meaning neither you nor your doctor will know if you are receiving the active drug or placebo. It plans to enroll 60 participants.

What's involved

You would take either CXA-10 or a placebo orally for 6 weeks. The study will monitor your lung function through spirometry tests for up to 18 weeks.

Compensation

Not stated in the trial record.

Follow-up

Your lung function will be measured through study completion, which is up to 18 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.